<rdf:RDF
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:j.0="http://www.ddmore.org/ontologies/webannotationtool#"
    xmlns:j.1="http://www.pharmml.org/ontology/"
    xmlns:j.2="http://www.pharmml.org/2013/10/PharmMLMetadata#" > 
  <rdf:Description rdf:about="http://repository.ddmore.eu/model/DDMODEL00000221">
    <j.2:model-tasks-in-scope rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006001"/>
    <j.2:model-has-description-long rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A tumor growth inhibition model describes the time-course of SLD. An indirect response model in which sunitinib stimulates tumor loss of SUVmax response best described the longitudinal SUVmax data, as assessed on FDG-PET scans. Inter-lesion variability in SUVmax is implemented similarly to inter-occasion variability. No disease progression was identified for SUVmax. A time-to-event model with a constant baseline hazard driven by the relative change in SUVmax from baseline for the lesion that responds the most was used to describe overall survival data.</j.2:model-has-description-long>
    <j.2:model-has-description rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Changes in FDG-PET standardized uptake values reflecting tumor metabolic activity was suggested as a predictor for long-term clinical outcome in GIST patients treated with anti-angiogenic drugs such as sunitinib. The model characterized the inter-individual and inter-lesion variability in SUVmax response and the predictive ability of SUVmax-related metrics on overall survival.</j.2:model-has-description>
    <j.2:model-field-purpose rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0000036"/>
    <j.0:model-origin-of-code-in-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No</j.0:model-origin-of-code-in-literature-controlled>
    <j.2:model-modelling-question rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006029"/>
    <j.2:model-research-stage rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006009"/>
    <j.2:model-modelling-question rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006037"/>
    <rdf:type rdf:resource="http://www.pharmml.org/ontology/PHARMMLO_0000001"/>
    <j.0:model-implementation-source-discrepancies-freetext rdf:datatype="http://www.w3.org/2001/XMLSchema#string">None</j.0:model-implementation-source-discrepancies-freetext>
    <j.0:model-implementation-conforms-to-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yes</j.0:model-implementation-conforms-to-literature-controlled>
  </rdf:Description>
</rdf:RDF>
